key: cord-0969172-i8y1kwul authors: Gonzalez-Rubio, Jesus; Navarro-Lopez, Carmen; Lopez-Najera, Elena; Lopez-Najera, Ana; Jimenez-Diaz, Lydia; Navarro-Lopez, Juan D.; Najera, Alberto title: Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm date: 2020-06-11 journal: Front Immunol DOI: 10.3389/fimmu.2020.01359 sha: f96b375b7233bb26475467ebd088c2bdd3e1e6f2 doc_id: 969172 cord_uid: i8y1kwul SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this “cytokine storm” and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients. INTRODUCTION SARS-CoV-2 is a new coronavirus that originated in Wuhan (Hubei Province, China) in December 2019, and it has already developed into a pandemic with worldwide spread (1) . It causes a severe acute respiratory syndrome (2) . SARS-CoV-2 is the third coronavirus outbreak to occur this current century, following severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) (3) . SARS-CoV-2 causes varying degrees of illness degrees. Fever and cough are dominant symptoms, but severe disease also occurs. Then, when COVID-19 patients' aggravation is presented, lung hyperinflammation may occur due to a virus-activated "cytokine storm" or cytokine release syndrome (CRS) (4) . Among different cytokines increased in such exacerbated response (5), Interleukin-6 (IL-6) in serum is mainly expected to predict the severity of SARS-CoV-2 pneumonia, as suppression of pro-inflammatory IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections (6) . In severe cases, SARS-CoV-2 has been shown to activate both the innate and adaptive immune system in the alveolar tissue, inducing the release of many cytokines and subsequent cytokine release syndrome (7) . During this response, levels of pro-inflammatory cytokines (including TNFa, interleukin (IL)-1b, IL-6, and IL-8) are increased (5) , which is also an important cause of death (8) . Therefore, one may think that controlling such crucial inflammatory factors could be a successful approach to reduce mortality in severe patients. The existence of a cholinergic anti-inflammatory pathway that modulates inflammatory responses during systemic inflammation has been demonstrated (9). a7-nicotinic acetylcholine receptor (a7nAChR) are known to be expressed on macrophages and to be essential for attenuating the inflammatory response by calcium influx-mediated activation during systemic inflammation (10) . The underlying mechanism conveys that activation of a7nAChR on infiltrated inflammatory cells, including macrophages and neutrophils, induces suppression of NF-kB activation (11) and secretion of pro-inflammatory cytokines and chemokines from inflammatory cells, including alveolar macrophages (12) . Interestingly, it has been already reported that nicotine, an a7nAChR agonist, exerts an antiinflammatory effect in a murine model of acute lung injury (13) . In fact, in other inflammatory diseases, such as ulcerative Colitis (UC), smoking or treatment with nicotine has demonstrated to significantly decrease the risk of developing the disease (14) . In this scenario, we hypothesize that nicotine could ameliorate the cytokine storm and severe related inflammatory response through a7nAChR-mediated cholinergic anti-inflammatory pathway. Nicotine is an accessible, existing, and approved treatment, with described side effects, that could likely reduce the rising mortality in the short term. Paradoxically, it is well-stablished that smokers have a significantly increased risk of chronic respiratory disease and acute respiratory infections. Current smokers have a higher risk of developing influenza compared to non-smokers (15) . Smoking is also significantly associated with MERS-CoV (16) , and there is no clear evidence for SARS-CoV-2 (17). In China, 54.0% of men are current smokers, whereas only 2.6% of women smoke (18) ; it should therefore be expected that the number of current smokers hospitalized with SARS-CoV-2 should be in a similar or larger percentage with male predominance. However, surprisingly, the number of hospitalized smoking patients in the Chinese outbreak is much lower than expected (19) (20) (21) (22) (23) . In Table 1 we show results comparing, both separately and using a combined approach, proportions of hospitalized smokers with SARS-CoV-2 in five different studies. Combined total current smokers was 159 compared to the 526·0 expected considering the male/female current smokers' ratio in China. We performed a χ 2 -test or Fisher's exact test to compare differences between observed and expected current smoker, for all the studies individually and combining all data, and we found significant differences in all cases (p < 0·001). Similar data have been reported for the ongoing pandemic in Europe and America, from patients in Italy (24) and US (25) , which strongly support our hypothesis. On the other hand, there are different formulations for nicotine administration: gums, patches, inhalators, nasal and oral sprays, sublingual tablets, and electronic cigarettes. Apart from the electronic cigarettes, which are quite new, the previous options are considered relatively safe, as most side effects are mild (26) . For instance, in the clinical practice transdermal nicotine is administered at high tolerated dosage for controlling clinical manifestations of chronic UC. For acute SARS-CoV-2 treatment to ameliorate hyperinflammation, nicotine dosage and pharmaceutical form could be chosen according to previous experience with UC (14, 27) . In addition to nicotine, it has been suggested that both selective α7nAChR agonists and allosteric modulators may be potential tools for the treatment of acute lung injury (12, 28, 29) . To our knowledge, no clinical trials of nicotine in COVID19 patients are currently being run. The most promising trial under run is the one using Tocilizumab, a blocker of IL-6 receptor for the treatment of cytokine storm (6), so it is expected to be an effective drug of severe patients. To further complete present hypothesis, factors such as age, smoking habits (vg. nicotine administration route), or any others that could influence smoker's health and susceptibility to the infection should be considered in future studies. It has been observed that the number of current smokers hospitalized in the SARS-CoV-2 outbreak in China is lower than expected when compared to the prevalence of smoking in this country. It has been described that, due to a cytokine storm, many patients are aggravated, showing severe inflation in the lungs. Our proposal may be easily tested in the short term, as it takes advantage of the existence of a cholinergic anti-inflammatory pathway that physiologically modulates inflammatory responses during systemic inflammation effect. Controlling the cytokine storm using nicotinic administration could then be expected to become a new method for the treatment of severe patients, as it has already been proved in UC patients. Just very recently, a group of recognized experts in the field recommended the "identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality" (8) . Current treatment with Tocilizumab seems to be useful to control cytokines storm. However, very strict criteria for its clinical use limits its availability, mainly due to price and adverse effects. Our proposal, recently supported by different non peer-reviewed additional reports (30, 31) , suggest that the treatment with nicotine by using any of the already approved pharmaceutical forms available in the market could reduce the lung inflammatory response by controlling the cytokines storm and, therefore, the number of patients in need of hospitalization for aggravation in the SARS-CoV-2 outbreak. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. JG-R and AN designed the study and collected data. JG-R, LJ-D, JN-L, and AN wrote the manuscript. All authors analyzed and interpreted the data. All authors contributed to the article and approved the submitted version. A Novel Coronavirus from Patients with Pneumonia in China A novel coronavirus associated with severe acute respiratory syndrome Origin and evolution of pathogenic coronaviruses Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Current concepts in the diagnosis and management of cytokine release syndrome The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality The use of antiinflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China COVID-19: consider cytokine storm syndromes and immunosuppression Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation NF-κB signaling in inflammation The cholinergic anti-inflammatory pathway: an innovative treatment strategy for respiratory diseases and their comorbidities Nicotine exerts an anti-inflammatory effect in a murine model of acute lung injury Nicotine and autoimmunity: the lotus' flower in tobacco Cigarette smoking and the occurrence of influenza -Systematic review Risk factors for primary middle east respiratory syndrome coronavirus illness in humans, Saudi Arabia Sex difference and smoking predisposition in patients with COVID-19 Prevalence and patterns of tobacco smoking among Chinese adult men and women: findings of the 2010 national smoking survey Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Wellaerated lung on admitting chest CT to predict adverse outcome in COVID-19 pneumonia Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -United States Nicotine replacement therapy for smoking cessation Transdermal nicotine for mildly to moderately active ulcerative colitis -A randomized, double-blind, placebo-controlled trial The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets? Nicotinic acetylcholine receptors: conventional and unconventional ligands and signaling Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications Cytokine release syndrome (CRS) and nicotine in COVID-19 patients: trying to calm the storm The authors thank Dr. Isabel Najera for helpful comments that greatly improved the manuscript. This manuscript was released as Pre-print at https://osf.io/chd2k/ on 2020/04/16 that has not been peer-reviewed (32) . The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2020 Gonzalez-Rubio, Navarro-Lopez, Lopez-Najera, Lopez-Najera, Jimenez-Diaz, Navarro-Lopez and Najera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.